Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$15.20
+3.0%
$14.62
$10.45
$21.69
$5.23B0.63571,036 shs298,368 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$87.45
+3.5%
$88.50
$77.10
$163.71
$4.85B0.76852,350 shs882,896 shs
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$175.61
+1.0%
$167.98
$55.92
$187.57
$5.58B1.15386,346 shs261,284 shs
NovoCure Limited stock logo
NVCR
NovoCure
$14.66
+4.3%
$12.23
$10.87
$34.13
$1.57B0.751.95 million shs1.20 million shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+2.98%+5.05%+3.69%+9.88%-20.27%
Glaukos Corporation stock logo
GKOS
Glaukos
+3.42%+9.38%-7.35%-15.51%-31.93%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
+1.04%+2.81%-0.55%+23.35%+147.23%
NovoCure Limited stock logo
NVCR
NovoCure
+4.34%+13.73%+21.36%-17.20%-5.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$15.20
+3.0%
$14.62
$10.45
$21.69
$5.23B0.63571,036 shs298,368 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$87.45
+3.5%
$88.50
$77.10
$163.71
$4.85B0.76852,350 shs882,896 shs
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$175.61
+1.0%
$167.98
$55.92
$187.57
$5.58B1.15386,346 shs261,284 shs
NovoCure Limited stock logo
NVCR
NovoCure
$14.66
+4.3%
$12.23
$10.87
$34.13
$1.57B0.751.95 million shs1.20 million shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+2.98%+5.05%+3.69%+9.88%-20.27%
Glaukos Corporation stock logo
GKOS
Glaukos
+3.42%+9.38%-7.35%-15.51%-31.93%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
+1.04%+2.81%-0.55%+23.35%+147.23%
NovoCure Limited stock logo
NVCR
NovoCure
+4.34%+13.73%+21.36%-17.20%-5.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.08
Hold$15.602.66% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.69
Moderate Buy$122.0039.51% Upside
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
2.79
Moderate Buy$172.17-1.96% Downside
NovoCure Limited stock logo
NVCR
NovoCure
2.38
Hold$27.5087.59% Upside

Current Analyst Ratings Breakdown

Latest NVCR, IRTC, BLCO, and GKOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$16.00
10/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$103.00
10/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$16.00
10/1/2025
Glaukos Corporation stock logo
GKOS
Glaukos
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$103.00
10/1/2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$158.00 ➝ $180.00
9/30/2025
NovoCure Limited stock logo
NVCR
NovoCure
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$18.00
9/29/2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$170.00 ➝ $193.00
9/27/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.12$1.93 per share7.88$18.57 per share0.82
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M13.08N/AN/A$13.91 per share6.29
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
$657.23M8.58N/AN/A$2.90 per share60.56
NovoCure Limited stock logo
NVCR
NovoCure
$630.16M2.60N/AN/A$3.33 per share4.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$0.78N/A15.831.50-5.58%2.33%1.12%10/29/2025 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$1.65N/AN/AN/A-21.43%-8.59%-6.61%11/3/2025 (Estimated)
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$113.29M-$2.93N/AN/AN/A-14.06%-90.03%-8.52%10/29/2025 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.56N/AN/AN/A-27.13%-47.74%-13.79%10/30/2025 (Confirmed)

Latest NVCR, IRTC, BLCO, and GKOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2025Q3 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.16N/AN/AN/A$1.28 billionN/A
10/29/2025Q3 2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$0.36N/AN/AN/A$184.75 millionN/A
10/29/2025Q3 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.42N/AN/AN/AN/AN/A
7/31/2025Q2 2025
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
-$0.53-$0.32+$0.21-$0.44$173.94 million$186.69 million
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.07+$0.01-$0.18$1.25 billion$1.28 billion
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26-$0.24+$0.02-$0.34$115.49 million$124.12 million
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.39-$0.36+$0.03-$0.36$153.87 million$158.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76
1.55
0.98
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
5.51
4.69
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
6.25
5.02
4.88
NovoCure Limited stock logo
NVCR
NovoCure
0.28
1.45
1.39

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
N/A
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
1.10%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500354.04 million351.35 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.35 million54.02 millionOptionable
iRhythm Technologies stock logo
IRTC
iRhythm Technologies
2,00032.13 million31.78 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.80 million105.63 millionOptionable

Recent News About These Companies

NovoCure (NASDAQ:NVCR) Given Neutral Rating at Wedbush
Novocure to Report Third Quarter 2025 Financial Results
NovoCure's (NVCR) "Neutral" Rating Reaffirmed at Wedbush
Strs Ohio Invests $759,000 in NovoCure Limited $NVCR
Novocure earns Japanese approval for tumor-treating fields
Insider Spends US$997k Buying More Shares In NovoCure

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$15.20 +0.44 (+2.95%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$14.90 -0.30 (-1.95%)
As of 10/3/2025 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$87.45 +2.96 (+3.50%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$85.42 -2.03 (-2.32%)
As of 10/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

iRhythm Technologies stock logo

iRhythm Technologies NASDAQ:IRTC

$175.61 +1.80 (+1.04%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$175.72 +0.11 (+0.06%)
As of 10/3/2025 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$14.66 +0.61 (+4.34%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$14.70 +0.04 (+0.27%)
As of 10/3/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.